Recursion Pharmaceuticals Stock Surges After Strong Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy RXRX?
Source: Benzinga
- Exceeding Market Expectations: Recursion Pharmaceuticals reported a loss per share of 21 cents, better than the expected loss of 27 cents, with quarterly revenue reaching $35.54 million, significantly surpassing the forecast of $24.59 million, indicating substantial progress in AI applications for drug discovery.
- Strong Stock Surge: The stock price of Recursion Pharmaceuticals rose by 11.33% to $3.93 during Wednesday's trading, reflecting a positive market reaction to its earnings report, although it remains 16.1% and 19.4% below its 100-day and 200-day moving averages, respectively.
- Technical Indicator Analysis: Currently, the stock trades 2.1% above its 20-day simple moving average, but the relative strength index (RSI) stands at 38.97, indicating neutral momentum, while the MACD shows a bearish signal, suggesting potential downward pressure despite the day's gains.
- CEO's Positive Outlook: CEO Najat Khan stated that Recursion has reached an inflection point, demonstrating that AI can not only participate in drug discovery but also generate clinical proof and durable value, laying a foundation for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.510
Low
5.00
Averages
7.75
High
11.00
Current: 3.510
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Pharmaceuticals Faces Major Challenges Ahead
- AI Drug Discovery Pioneer: Recursion Pharmaceuticals leverages artificial intelligence for drug discovery, yet despite being founded in 2013, it currently lacks approved products and faces fierce competition, impacting its market performance.
- Slow Clinical Trial Progress: The company plans to release early-stage clinical trial data in the next 12 to 18 months; however, as these are primarily Phase 1 studies focusing on safety rather than efficacy, significant stock price impact is unlikely.
- Partnerships Enhance Funding: By partnering with pharmaceutical giants like Roche and Sanofi, Recursion can access funding more easily, yet it still faces substantial clinical and regulatory hurdles to achieve product approval.
- Increased Investment Risks: Although some candidates like REC-617 show promise, the overall risk for the company remains high, suggesting that risk-averse investors should maintain distance to avoid further losses.
See More
Recursion Pharmaceuticals Leverages AI to Accelerate R&D
- AI R&D Prospects: Recursion Pharmaceuticals is leveraging artificial intelligence to accelerate drug discovery; however, it has yet to launch any approved products and faces significant clinical and regulatory hurdles, indicating a high-risk business model.
- Clinical Trial Progress: The company plans to release data from early-stage clinical trials over the next 12 to 18 months, but since these are primarily phase 1 studies focusing on safety and tolerability, they are unlikely to significantly impact stock performance.
- Diminishing Competitive Edge: While Recursion aimed to gain a competitive advantage through AI, its market position is eroding as more peers adopt similar technologies, prompting investors to carefully assess the associated risks.
- Partnerships: Recursion has formed partnerships with pharmaceutical giants like Roche and Sanofi, which provide funding support; however, it still faces substantial clinical and regulatory challenges to secure product approvals.
See More
PacBio Appoints New Board Member
- New Board Member: PacBio has appointed Dr. Christopher Gibson to its Board of Directors, who is the co-founder of Recursion and brings extensive experience in AI-driven drug discovery, which will support PacBio's long-term vision.
- AI and Biotechnology Integration: Under Gibson's leadership, Recursion successfully integrated large-scale biological data generation with machine learning, industrializing the drug discovery process and enhancing the company's competitiveness in the biotech sector.
- Strategic Importance: Gibson emphasized that PacBio's high-quality long-read sequencing technology generates the richest biological datasets in the industry, and that algorithmic approaches will accelerate discovery and development in healthcare, presenting significant market potential.
- Future Outlook: PacBio aims to leverage Gibson's expertise to accelerate decoding biological complexity for disease diagnosis and treatment, further solidifying its leadership position in the life sciences technology field.
See More
PacBio Appoints New Board Member
- New Board Member: PacBio has appointed Dr. Christopher Gibson, co-founder of Recursion, to its Board of Directors, whose extensive experience in AI-driven drug discovery is expected to enhance PacBio's strategic development in genomics.
- Technological Integration Advantage: Under Dr. Gibson's leadership at Recursion, the successful integration of large-scale biological data with machine learning improved drug discovery efficiency, a capability that will directly support PacBio's data-driven discovery in high-throughput genomics.
- Biological Data Platform Development: At Recursion, Dr. Gibson developed a proprietary platform capable of generating and analyzing multimodal datasets, which will provide crucial support for PacBio in accelerating clinical development and patient selection, enhancing its market competitiveness.
- Future Development Vision: Dr. Gibson emphasized that PacBio's high-quality long-read sequencing technology will provide a rich foundation for biological data analysis, and combined with AI-driven analytics, it will accelerate discoveries and diagnostics in healthcare, showcasing significant market potential.
See More
PACBIO NAMES CHRIS GIBSON TO ITS BOARD OF DIRECTORS
- Announcement of Appointment: PACBIO has announced the appointment of Chris Gibson to its Board of Directors.
- Significance of Appointment: This addition is expected to enhance the board's expertise and guidance in the company's strategic direction.
See More
Recursion Pharmaceuticals Q4 2025 Earnings Call Insights
- Financial Transformation: Recursion ended 2025 with $754 million in cash, achieving a 35% year-over-year reduction in operating expenses and actual spending 10% below earlier guidance, indicating significant progress in financial management and enhancing future investment flexibility.
- Clinical Milestone Progress: The company reached its fifth milestone with Sanofi and achieved the first positive clinical proof of concept with FAP, demonstrating the effectiveness of its AI-driven platform in drug development, which may attract more attention for future collaborations and investments.
- Strategic Execution and Outlook: Management expects cash operating expenses for 2026 to be under $390 million, with cash flow projections including over $500 million in partnership inflows, reflecting confidence in advancing clinical programs and partnerships.
- Risks and Challenges: Despite progress in operational efficiency, management highlighted the inherent risks of drug discovery with a 90% failure rate, emphasizing the importance of rapid decision-making and efficient capital allocation to navigate future uncertainties.
See More
Recursion Pharmaceuticals Faces Major Challenges Ahead
- AI Drug Discovery Pioneer: Recursion Pharmaceuticals leverages artificial intelligence for drug discovery, yet despite being founded in 2013, it currently lacks approved products and faces fierce competition, impacting its market performance.
- Slow Clinical Trial Progress: The company plans to release early-stage clinical trial data in the next 12 to 18 months; however, as these are primarily Phase 1 studies focusing on safety rather than efficacy, significant stock price impact is unlikely.
- Partnerships Enhance Funding: By partnering with pharmaceutical giants like Roche and Sanofi, Recursion can access funding more easily, yet it still faces substantial clinical and regulatory hurdles to achieve product approval.
- Increased Investment Risks: Although some candidates like REC-617 show promise, the overall risk for the company remains high, suggesting that risk-averse investors should maintain distance to avoid further losses.
See More
Recursion Pharmaceuticals Leverages AI to Accelerate R&D
- AI R&D Prospects: Recursion Pharmaceuticals is leveraging artificial intelligence to accelerate drug discovery; however, it has yet to launch any approved products and faces significant clinical and regulatory hurdles, indicating a high-risk business model.
- Clinical Trial Progress: The company plans to release data from early-stage clinical trials over the next 12 to 18 months, but since these are primarily phase 1 studies focusing on safety and tolerability, they are unlikely to significantly impact stock performance.
- Diminishing Competitive Edge: While Recursion aimed to gain a competitive advantage through AI, its market position is eroding as more peers adopt similar technologies, prompting investors to carefully assess the associated risks.
- Partnerships: Recursion has formed partnerships with pharmaceutical giants like Roche and Sanofi, which provide funding support; however, it still faces substantial clinical and regulatory challenges to secure product approvals.
See More
PacBio Appoints New Board Member
- New Board Member: PacBio has appointed Dr. Christopher Gibson to its Board of Directors, who is the co-founder of Recursion and brings extensive experience in AI-driven drug discovery, which will support PacBio's long-term vision.
- AI and Biotechnology Integration: Under Gibson's leadership, Recursion successfully integrated large-scale biological data generation with machine learning, industrializing the drug discovery process and enhancing the company's competitiveness in the biotech sector.
- Strategic Importance: Gibson emphasized that PacBio's high-quality long-read sequencing technology generates the richest biological datasets in the industry, and that algorithmic approaches will accelerate discovery and development in healthcare, presenting significant market potential.
- Future Outlook: PacBio aims to leverage Gibson's expertise to accelerate decoding biological complexity for disease diagnosis and treatment, further solidifying its leadership position in the life sciences technology field.
See More
PacBio Appoints New Board Member
- New Board Member: PacBio has appointed Dr. Christopher Gibson, co-founder of Recursion, to its Board of Directors, whose extensive experience in AI-driven drug discovery is expected to enhance PacBio's strategic development in genomics.
- Technological Integration Advantage: Under Dr. Gibson's leadership at Recursion, the successful integration of large-scale biological data with machine learning improved drug discovery efficiency, a capability that will directly support PacBio's data-driven discovery in high-throughput genomics.
- Biological Data Platform Development: At Recursion, Dr. Gibson developed a proprietary platform capable of generating and analyzing multimodal datasets, which will provide crucial support for PacBio in accelerating clinical development and patient selection, enhancing its market competitiveness.
- Future Development Vision: Dr. Gibson emphasized that PacBio's high-quality long-read sequencing technology will provide a rich foundation for biological data analysis, and combined with AI-driven analytics, it will accelerate discoveries and diagnostics in healthcare, showcasing significant market potential.
See More
PACBIO NAMES CHRIS GIBSON TO ITS BOARD OF DIRECTORS
- Announcement of Appointment: PACBIO has announced the appointment of Chris Gibson to its Board of Directors.
- Significance of Appointment: This addition is expected to enhance the board's expertise and guidance in the company's strategic direction.
See More
Recursion Pharmaceuticals Q4 2025 Earnings Call Insights
- Financial Transformation: Recursion ended 2025 with $754 million in cash, achieving a 35% year-over-year reduction in operating expenses and actual spending 10% below earlier guidance, indicating significant progress in financial management and enhancing future investment flexibility.
- Clinical Milestone Progress: The company reached its fifth milestone with Sanofi and achieved the first positive clinical proof of concept with FAP, demonstrating the effectiveness of its AI-driven platform in drug development, which may attract more attention for future collaborations and investments.
- Strategic Execution and Outlook: Management expects cash operating expenses for 2026 to be under $390 million, with cash flow projections including over $500 million in partnership inflows, reflecting confidence in advancing clinical programs and partnerships.
- Risks and Challenges: Despite progress in operational efficiency, management highlighted the inherent risks of drug discovery with a 90% failure rate, emphasizing the importance of rapid decision-making and efficient capital allocation to navigate future uncertainties.
See More
